In December, the cell therapy company Amniotics presented a new strategic direction with a focus on business development and completion of clinical trials. The company's prioritized programs are the clinical lung project PulmoStem and the preclinical project AMNI-NK003 in oncology. To take the next step, Amniotics is now conducting a rights issue of approximately SEK 36,1 million. CEO Marcus Larsson visited BioStock's studio to present the company and tell more about Amniotic's focus areas.
Se Amniotic vd Marcus Larsson present the company below.
The invitation to interested persons to subscribe for units in Amniotics will only be made through the prospectus published on February 17, 2023. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and published on www.amniotics.com.